Biocon

₹298.8 -5.3 | 1.7%

WEBSITE BSE:532523 NSE : BIOCON LTD. 13 May, 11:11

Market Cap ₹35868 Cr.

Stock P/E 29.9

P/B 1.8

Current Price ₹298.8

Book Value ₹ 164.6

Face Value 5

52W High ₹314.7

Dividend Yield 0.5%

52W Low ₹ 217.5

Edit Ratio

Biocon Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Biocon Limited is an India-based biopharmaceutical company that focuses to deal with diabetes, cancers and autoimmune diseases. The Company is likewise focused on developing novel treatments for diabetes, oncology and immunology. The Company's corporations section includes Generics, Biosimilars, Novel Biologics and Research Services. The Company's Generic Formulations and API products consist of Rosuvastatin, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company's portfolio consists of ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

Biocon Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Biocon Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	1840	2174	2409	2140	2320	2941	3774	3423	3462	3954
Other Income	105	48	67	78	65	79	155	94	158	566
Total Income	1945	2223	2476	2217	2384	3020	3929	3516	3620	4519
Total Expenditure	1395	1686	1817	1740	1849	2297	2777	2708	2721	3027
Operating Profit	551	537	659	477	535	723	1152	808	900	1492
Interest	23	15	11	20	30	120	249	233	248	267
Depreciation	202	206	212	218	231	301	364	358	389	415
Exceptional Income / Expenses	-70	0	-41	0	-17	-271	-3	0	-24	21
Profit Before Tax	257	316	396	240	257	30	537	217	239	832
Provision for Tax	46	49	59	30	147	-5	82	35	42	55
Profit After Tax	210	267	337	210	110	35	455	182	197	777
Adjustments	-72	-80	-98	-66	-63	-77	-141	-81	-71	-117
Profit After Adjustments	138	187	239	144	47	-42	313	101	126	660
Adjusted Earnings Per Share	1.2	1.6	2	1.2	0.4	-0.3	2.6	0.8	1	5.5

Biocon Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	2485	2877	3090	3347	3891	4123	5514	6301	7143	8184	11174	14613
Other Income	125	245	215	231	285	381	414	508	605	690	768	973
Total Income	2610	3123	3305	3579	4177	4504	5929	6808	7748	8874	11942	15584
Total Expenditure	2014	2380	2556	2732	3040	3469	4391	5044	5841	6691	9055	11233
Operating Profit	596	743	749	847	1137	1035	1538	1765	1907	2183	2888	4352
Interest	8	2	9	29	26	62	71	65	58	68	419	997
Depreciation	179	204	221	249	277	385	448	552	715	814	1113	1526
Exceptional Income / Expenses	202	0	105	161	0	0	195	68	13	-111	-291	-6
Profit Before Tax	610	538	624	751	850	610	1215	1215	1068	983	897	1825
Provision for Tax	98	107	96	142	162	157	212	315	222	212	254	214
Profit After Tax	513	431	528	609	688	453	1003	900	846	772	643	1611
Adjustments	-4	-17	-31	-59	-76	-81	-97	-152	-106	-123	-180	-410
Profit After Adjustments	509	414	497	550	612	372	905	748	741	648	463	1200
Adjusted Earnings Per Share	4.2	3.4	4.1	4.6	5.1	3.1	7.5	6.2	6.2	5.4	3.9	9.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	37%	21%	22%	16%
Operating Profit CAGR	32%	18%	23%	17%
PAT CAGR	-17%	-11%	7%	2%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	21%	-8%	3%	15%
ROE Average	5%	9%	12%	14%
ROCE Average	5%	8%	11%	13%

Biocon Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2695	3027	3271	4034	4838	5181	6098	6706	7627	8433	17867
Minority's Interest	65	82	172	266	376	468	609	677	881	1038	4622
Borrowings	164	606	770	2072	2108	1790	1526	1222	2962	3999	15291
Other Non-Current Liabilities	502	656	608	349	196	217	597	1463	2535	2804	5452
Total Current Liabilities	990	1380	1555	1666	1678	2141	3039	4008	4210	3828	8511
Total Liabilities	4416	5751	6375	8387	9197	9796	11868	14076	18215	20101	51742
Fixed Assets	1510	1525	1630	1748	3625	3700	4471	5971	6364	6569	29468
Other Non-Current Assets	666	1587	2183	2667	1524	1948	2508	2780	4250	5149	9940
Total Current Assets	2240	2639	2563	3971	4048	4149	4889	5325	7600	8382	12334
Total Assets	4416	5751	6375	8387	9197	9796	11868	14076	18215	20101	51742

Biocon Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	369	474	557	458	758	710	449	659	825	897	654
Cash Flow from Operating Activities	471	561	211	371	640	662	1155	1283	1160	1177	1853
Cash Flow from Investing Activities	-376	-938	-509	-1142	-499	-684	-714	-1559	-3625	-1699	-14282
Cash Flow from Financing Activities	-9	426	186	1068	-178	-240	-242	388	2564	242	13049
Net Cash Inflow / Outflow	87	49	-112	297	-36	-262	199	112	99	-280	619
Closing Cash & Cash Equivalent	474	557	463	758	710	449	659	825	897	654	1295

Biocon Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	4.24	3.45	4.15	4.59	5.1	3.1	7.54	6.24	6.17	5.4	3.85
CEPS(Rs)	5.77	5.29	6.25	7.15	8.04	6.99	12.09	12.1	13.01	13.21	14.63
DPS(Rs)	7.5	5	0.83	0.83	0.5	1	0.5	0	0	0.5	1.5
Book NAV/Share(Rs)	21.59	24.21	26.93	33.1	39.74	42.6	50.17	54.97	62.27	68.53	146.53
Core EBITDA Margin(%)	18.61	17.08	17.11	18.22	21.71	15.85	20.38	19.95	18.23	18.18	18.8
EBIT Margin(%)	24.43	18.51	20.27	23.09	22.33	16.26	23.32	20.31	15.76	12.8	11.67
Pre Tax Margin(%)	24.11	18.45	19.99	22.22	21.67	14.77	22.03	19.28	14.95	11.98	7.96
PAT Margin (%)	20.26	14.78	16.92	18.02	17.55	10.97	18.18	14.28	11.85	9.4	5.7
Cash Profit Margin (%)	27.35	21.77	24	25.37	24.61	20.3	26.3	23.05	21.86	19.32	15.57
ROA(%)	12.27	8.47	8.72	8.25	7.83	4.77	9.26	6.94	5.24	4.03	1.79
ROE(%)	21.5	15.68	17.22	16.91	15.74	9.17	18.01	14.26	12.03	9.83	4.98
ROCE(%)	22.47	15.75	15.3	14.33	12.83	9.21	16.12	14.35	10.56	8.3	5.37
Receivable days	72.22	69.48	80.09	80.16	74.35	86.05	77.96	72.86	70.03	79.49	91.14
Inventory Days	56.01	48.54	48.47	53.71	54.81	60	58.05	71.47	84.38	92.6	105.87
Payable days	121.15	106.58	112.86	146.96	170.25	194.65	212.04	231.48	230.92	209.62	278.58
PER(x)	10.79	20.5	18.88	17.52	37.04	95.74	40.49	43.4	66.25	61.95	53.54
Price/Book(x)	2.12	2.92	2.91	2.43	4.75	6.97	6.09	4.92	6.57	4.88	1.41
Dividend Yield(%)	2.73	1.18	1.06	1.04	0.26	0.17	0.16	0	0	0.15	0.73
EV/Net Sales(x)	2.05	2.97	3.1	3.16	6.15	8.87	6.89	5.41	7.19	5.29	3.59
EV/Core EBITDA(x)	8.54	11.49	12.78	12.49	21.05	35.35	24.71	19.32	26.93	19.85	13.9
Net Sales Growth(%)	19.11	15.77	7.39	8.34	16.24	5.97	33.73	14.26	13.37	14.57	36.54
EBIT Growth(%)	52.78	-12.76	17.35	23.32	12.18	-23.32	91.48	-0.47	-12.06	-6.64	25.26
PAT Growth(%)	51.51	-15.97	22.66	15.27	12.97	-34.15	121.28	-10.25	-5.96	-8.82	-16.67
EPS Growth(%)	50.38	-18.69	20.2	10.66	11.21	-39.16	143.1	-17.35	-1.03	-12.48	-28.64
Debt/Equity(x)	0.1	0.3	0.35	0.62	0.48	0.44	0.4	0.4	0.58	0.6	1.01
Current Ratio(x)	2.26	1.91	1.65	2.38	2.41	1.94	1.61	1.33	1.81	2.19	1.45
Quick Ratio(x)	1.87	1.64	1.37	2.09	2.14	1.61	1.29	0.97	1.36	1.59	0.95
Interest Cover(x)	76.33	317.29	71.12	26.64	33.68	10.92	18.14	19.72	19.5	15.54	3.14
Total Debt/Mcap(x)	0.05	0.1	0.12	0.26	0.1	0.06	0.07	0.08	0.09	0.12	0.72

Biocon Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64
FII	16	15.62	16.31	15.79	14.42	10.2	9.52	7.96	6.55	5.63
DII	7.36	8.36	7.72	7.76	8.63	11.9	12.59	14.08	14.51	13.68
Public	15.99	15.38	15.33	15.81	16.31	17.27	17.26	17.32	18.3	20.05
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8
FII	19.21	18.75	19.58	18.96	17.31	12.25	11.43	9.56	7.87	6.76
DII	8.84	10.04	9.27	9.32	10.36	14.28	15.11	16.91	17.42	16.42
Public	19.2	18.47	18.41	18.98	19.58	20.73	20.72	20.79	21.97	24.07
Others	0	0	0	0	0	0	0	0	0	0
Total	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06

Pros

Cons

Company has a low return on equity of 9% over the last 3 years.
Debtor days have increased from 209.62 to 278.58days.
The company has delivered a poor profit growth of 7% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Biocon News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Biocon

Add Watchlist

Biocon Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Biocon Share Price

Alert Data

Quarterly Price

Peer Comparison

Biocon Quarterly Results

Biocon Profit & Loss

Growth Rates

Biocon Balance Sheet

Biocon Cash Flow

Biocon Ratios

Biocon Shareholding Pattern

Biocon News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!